JAZZ

#3398
Jazz Pharmaceuticals plc - Ordinary Shares
2.3 6 USD
+0.47%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
2.36
2.36
Faixa anual
2.36
243.32
Mudança diária
+0.47%
Mudança mensal
-98.83%
Mudança em 6 meses
-98.64%
Mudança anual
-98.31%
Fechamento anterior
2.3 5
Open
2.3 6
Mínimo
2.3 6
High
2.3 6
Volume
137
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 148.38 M
  • Employee 2 890
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-29.11
Índice preço/fluxo de caixa
2.43

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

Notícias